Journal of Neural Transmission

, Volume 107, Issue 5, pp 563–579

CSF levels of tau, β-amyloid1–42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

Authors

  • M. Sjögren
    • Institute of Clinical Neuroscience, Göbteborg University, Sahlgrenska University Hospital, Mölndal
  • L. Minthon
    • Department of Community Medicine, Lund University, Neuropsychiatric Clinic, Malmö University Hospital, Malmö
  • P. Davidsson
    • Institute of Clinical Neuroscience, Göbteborg University, Sahlgrenska University Hospital, Mölndal
  • A. -K. Granérus
    • Department of Geriatrics, University of Health Sciences, Linköping, Sweden
  • A. Clarberg
    • Department of Community Medicine, Lund University, Neuropsychiatric Clinic, Malmö University Hospital, Malmö
  • H. Vanderstichele
    • Innogenetics, Ghent, Belgium
  • E. Vanmechelen
    • Innogenetics, Ghent, Belgium
  • A. Wallin
    • Institute of Clinical Neuroscience, Göbteborg University, Sahlgrenska University Hospital, Mölndal
  • K. Blennow
    • Institute of Clinical Neuroscience, Göbteborg University, Sahlgrenska University Hospital, Mölndal

DOI: 10.1007/s007020070079

Cite this article as:
Sjögren, M., Minthon, L., Davidsson, P. et al. J Neural Transm (2000) 107: 563. doi:10.1007/s007020070079

Summary.

Cerebrospinal fluid (CSF) levels of tau, β-amyloid1–42 and growth-associated protein 43 (GAP-43) were studied in patients with frontotemporal dementia (FTD; n = 17), Alzheimer's disease (AD; n = 60), subcortical white-matter dementia (SWD; n = 24), Parkinson's disease (PD; n = 23) and dysthymia (n = 19) and in age-matched controls (n = 32). CSF-tau was significantly increased only in AD, and CSF-β-amyloid1–42 was significantly decreased in AD and SWD as compared to controls, and in AD compared to FTD. CSF-GAP-43 was significantly decreased only in PD. The GAP-43/tau ratio was decreased in all the patient groups except the dysthymia group compared to controls. A positive correlation was found between CSF-GAP-43 and CSF-tau in all groups. The results suggest normal levels of CSF-tau and CSF-β-amyloid1–42 in FTD, which will aid in the clinical separation of FTD from AD. In SWD, decreased levels of CSF-β-amyloid1–42 suggest concomitant involvement of vascular and amyloid protein mechanisms.

Keywords: Alzheimer's disease, frontotemporal dementia, vascular dementia, subcortical, white matter, Parkinson's disease, cerebrospinal fluid, GAP-43, tau, β-amyloid, biochemical marker.

Copyright information

© Springer-Verlag Wien 2000